GSK and ChemoCentryx take novel Crohn's therapy into Phase III
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and ChemoCentryx have begun full Phase III development for their potential oral anti-inflammatory treatment for Crohn's disease, GSK1605786 (formerly Traficet-EN).